Atea Pharmaceuticals (AVIR) vs Evommune (EVMN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Atea Pharmaceuticals (AVIR) has outperformed Evommune (EVMN) over the past year, gaining 33.3% versus a loss of 62.4%. Atea Pharmaceuticals is the larger company by market cap ($318.0 million vs $291.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVIR | EVMN |
|---|---|---|
| Share price | $3.96 | $7.04 |
| Market cap | $318.00M | $291.10M |
| 1-day change | +0.76% | -2.76% |
| YTD return | +10.92% | -58.88% |
| 1-year return | +33.33% | -62.37% |
| 5-year return | -51.35% | — |
| EPS (TTM) | $-1.95 | $-3.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $13.00M |
| Revenue growth (YoY) | — | +85.71% |
| Net income (latest FY) | $-158.35M | $-68.87M |
| Operating margin | — | -623.62% |
| Net margin | — | -529.77% |
| 52-week high | $6.45 | $33.20 |
| 52-week low | $2.96 | $4.94 |
| Distance from 52-week high | -38.60% | -78.80% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +127.27% | +210.94% |
| Average volume | 290.60K | 841.65K |
| Shares outstanding | 80.30M | 41.35M |
| Employees | 55 | 48 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AVIR has outperformed EVMN by 95.7 percentage points over the past year.
About Atea Pharmaceuticals
AVIR stock →Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
About Evommune
EVMN stock →Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
AVIR vs EVMN FAQ
Which is bigger, Atea Pharmaceuticals or Evommune?
Atea Pharmaceuticals (AVIR) is larger, with a market capitalization of $318.00M compared with $291.10M for Evommune (EVMN).
Which stock has performed better over the past year, AVIR or EVMN?
AVIR returned +33.33% over the past 12 months, compared with -62.37% for EVMN (price return, excluding dividends). Past performance does not predict future results.
Are Atea Pharmaceuticals and Evommune in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.